Research programme: immune therapeutics - Eisai Andover innovative Medicines (AiM) Institute

Drug Profile

Research programme: immune therapeutics - Eisai Andover innovative Medicines (AiM) Institute

Alternative Names: AiM institute immune therapeutics

Latest Information Update: 21 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Andover Innovative Medicines Institute
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Brain disorders; Cancer; Immunological disorders

Most Recent Events

  • 13 Jun 2018 Genetics Guided Dementia Discovery plans to introduce a compound identified through its immuno-dementia research into the clinic by 2020
  • 15 Sep 2016 Early research in Immunological disorders, Cancer and Brain disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top